Is Your Oncology Analytics Organization Best in Class Yet?

Posted by Arup Das on Oct 25, 2018 8:00:00 AM

Arun Jain co-wrote this blog post with Arup Das.

Imagine a world where oncology analytics transform the way that a pharma manufacturer engages with its customer: Sales reps have real-time insight into where patients are being diagnosed. Accurate predictions help them anticipate when to follow up with a customer with a relevant message about their soon-to-relapse patient. Customers give them unencumbered access because they trust that the manufacturer will engage with them through their preferred channels at the right cadence. Does this sound too good to be true? Some oncology companies are already exploring these possibilities today, but according to ZS’s recent benchmarking study of oncology analytics organizations, many are not there yet in their analytics maturity and are missing out on critical opportunities to engage their customers when it matters most.


>
Read More

How to Pay for Transformative Cell and Gene Therapies

Posted by Bernadette Bourjolly on Oct 13, 2017 8:00:00 AM

Malik Kaman co-wrote this blog post with Bernadette Bourjolly. 

After two decades of failures and setbacks, it’s an exciting time in the field of cell and gene therapies as we witness pioneering advances in a wide range of indications in areas including blood cancers, immunodeficiency and ophthalmology. While cell and gene therapies represent a potential paradigm shift for the treatment of cancer and rare genetic disorders, funding and reimbursement of these unconventional therapies pose major challenges. 


>
Read More

Oncology Pathways: Who Controls the Menu at Healthcare’s ‘Dinner for Three’?

Posted by Paul Darling on Mar 21, 2016 8:00:00 AM

In recent years, payers have made an effort to exert more control over physicians’ treatment decisions, especially in oncology. They’ve created clinical pathways that set out treatment guidelines and use prior authorizations and step therapy to encourage physicians to select payers’ preferred protocols and drugs.


>
Read More